187 related articles for article (PubMed ID: 34748702)
21. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
22. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
[TBL] [Abstract][Full Text] [Related]
23. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
24. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
25. Re(CO)
Lipowska M; Jarkas N; Voll RJ; Nye JA; Klenc J; Goodman MM; Taylor AT
Nucl Med Biol; 2018 Mar; 58():42-50. PubMed ID: 29367095
[TBL] [Abstract][Full Text] [Related]
26. Simple and rapid radiosynthesis of N-
Sun A; Liu S; Tang X; Nie D; Tang G; Zhang Z; Wen F; Wang X
Nucl Med Biol; 2017 Jun; 49():38-43. PubMed ID: 28301817
[TBL] [Abstract][Full Text] [Related]
27. Canagliflozin: first global approval.
Elkinson S; Scott LJ
Drugs; 2013 Jun; 73(9):979-88. PubMed ID: 23729000
[TBL] [Abstract][Full Text] [Related]
28. Efficient radiosynthesis and preclinical evaluation of [
Singleton TA; Bdair H; Bailey JJ; Choi S; Aliaga A; Rosa-Neto P; Schirrmacher R; Bernard-Gauthier V; Kostikov A
J Labelled Comp Radiopharm; 2020 Mar; 63(3):144-150. PubMed ID: 31919878
[TBL] [Abstract][Full Text] [Related]
29. Positron Emission Tomography Imaging of Tumor Apoptosis with a Caspase-Sensitive Nano-Aggregation Tracer [
Chen Z; Rao J
Methods Mol Biol; 2018; 1790():181-195. PubMed ID: 29858792
[TBL] [Abstract][Full Text] [Related]
30. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T
Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590
[TBL] [Abstract][Full Text] [Related]
32. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
33. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
35. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
[TBL] [Abstract][Full Text] [Related]
36. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
37. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
38. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
[TBL] [Abstract][Full Text] [Related]
39. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
40. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
